Quanterix Revenue and Competitors

Claim your profile

Boston, MA USA

Location

#5169

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Quanterix's estimated annual revenue is currently $37.6M per year.(i)
  • Quanterix received $8.5M in venture funding in August 2017.
  • Quanterix's estimated revenue per employee is $64,771
  • Quanterix's total funding is $533.3M.

Employee Data

  • Quanterix has 581 Employees.(i)
  • Quanterix grew their employee count by 26% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$300.5M19393%N/AN/A
#2
$54.1M2792%$85.2MN/A

Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company's ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts.

keywords:Analytics,Biotechnology,Enterprise Software,Healthcare,Medical Diagnostics,Pharmaceuticals

$533.3M

Total Funding

581

Number of Employees

$37.6M

Revenue (est)

26%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Quanterix News

2022-04-17 - Quanterix wins FDA breakthrough nod for MS diagnostic ...

Billerica, Massachusetts-based Quanterix designed its Simoa neurofilament light chain (NfL) plasma test as a prognostic aid in assessing the...

2022-04-17 - Quanterix gets FDA Breakthrough Device designation for plasma test for multiple sclerosis

Quanterix (NASDAQ:QTRX) on Friday said its Simoa neurofilament light chain plasma test has been granted Breakthrough Device designation by...

2022-04-17 - Quanterix Granted Breakthrough Device Designation from ...

Quanterix is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health. The company's digital...

2021-06-05 - Quanterix : Q1 GAAP revenue including grant revenue $27.2M; Q1 non-GAAP revenue $24.9M, an increase of 58% versus prior year

Q1 GAAP revenue including grant revenue $27.2M; Q1 non-GAAP revenue $24.9M, an increase of 58% versus prior year Billerica, Mass. -May 5, 2021 - Quanterix Corporation (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, t ...

2021-05-06 - QUANTERIX CORPORATION Quanterix : Q1 GAAP revenue including grant revenue $27.2M; Q1 non-GAAP revenue $24.9M, an increase of 58% versus prior year

Q1 GAAP revenue including grant revenue $27.2M; Q1 non-GAAP revenue $24.9M, an increase of 58% versus prior year Billerica, Mass. -May 5, 2021 - Quanterix Corporation (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, t ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$133.2M592N/AN/A
#2
$212M6282%N/A
#3
$194.8M65212%N/A
#4
$141.7M72314%N/A
#5
$145.7M72812%$45M

Quanterix Funding

DateAmountRoundLead InvestorsReference
2008-08-26$15.0MAARCH Venture Partners, Bain Capital VenturesArticle
2016-03-24$46.0MDARCH Overage FundArticle
2017-08-04$8.5MUndisclosedT. Rowe Price Associates, Inc.Article